RecruitingEsophageal CancerGastric AdenocarcinomaHER2 Gene Mutation
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Sponsor: Memorial Sloan Kettering Cancer Center
You may qualify if…
- ✓ Age 18 years or older at time of signing informed consent.
- ✓ ECOG performance status 0-1.
- ✓ HER2+ esophageal, GEJ, or gastric adenocarcinoma biopsy or resection specimen as defined by local HER2 IHC3+ or IHC 2+/FISH\>2.0 expression.
- ✓ Complete surgical resection of the primary tumor must be achievable
- ✓ Demonstrate adequate organ function as defined in Table 1.
- ✓ Table 1 - Organ Function Requirements for Eligibility Hematological
- ✓ Absolute neutrophil count (ANC): ≥1,500 /mcL
- ✓ Platelets: ≥100,000 / mcL
You may not qualify if…
- ✕ Presence of metastatic or recurrent disease.
- ✕ Has received prior treatment for esophagogastric cancer
- ✕ Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.
- ✕ Has received prior therapy with an anti-HER2 agent
- ✕ Left ventricular ejection fraction \<50% within 1 month of screening by MUGA or echocardiogram. Patients with an ejection fraction 45-49% may be permissible in the absence of any cardiac symptoms, if cleared by a cardiologist, and per the investigator's discresion.
- ✕ Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- ✕ Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- ✕ Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast premedication) may be enrolled.
Where it's recruiting
Massachusetts
Boston
New Jersey
Basking Ridge · Middletown · Montvale
New York
Commack · Harrison · New York · Uniondale
Pennsylvania
Philadelphia
Texas
Houston
Source: ClinicalTrials.gov · NCT06123338 · last updated 2026-05-28